Targeting the JAK/STAT Signaling Pathway for Breast Cancer

(E-pub Ahead of Print)

Author(s): Fei Shao, Xiaonan Pang, Gyeong Hun Baeg*

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer
Call for Editor


Breast cancer is the most common malignant tumor in women worldwide. Traditional ways of treatment, includ-ing radiotherapy and endocrine therapy, for breast cancer have inevitable side effects. In recent decades, targeted therapies for breast cancer have rapidly advanced and shown a promising future. The JAK/STAT signaling pathway has been shown to play important roles in tumorigenesis, maintenance and metastasis of breast cancer. Hence, many small molecule inhibi-tors of JAK and STAT proteins have been developed. These inhibitors exhibit potent inhibitory effects on breast cancer in both cellular and animal models, and even some of them have already been in clinical trials. This review article discussed the JAK/STAT signal transduction pathway in the pathogenesis of breast cancer, and the potential for the application of JAK/STAT inhibitors in breast cancer treatment.

Keywords: Breast cancer, JAK/STAT pathway, Inhibitors, Targeted therapy, Therapeutics, STAT3 dimerization

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867328666201207202012
Price: $95

Article Metrics

PDF: 509